Ageing Research Reviews,
Journal Year:
2024,
Volume and Issue:
94, P. 102192 - 102192
Published: Jan. 14, 2024
Alzheimer's
disease
(AD)
is
the
most
common
neurodegenerative
characterized
by
cognitive
impairment
with
few
therapeutic
options.
Despite
many
failures
in
developing
AD
treatment
during
past
20
years,
significant
advances
have
been
achieved
passive
immunotherapy
of
very
recently.
Here,
we
review
characteristics,
clinical
trial
data,
and
mechanisms
action
for
monoclonal
antibodies
(mAbs)
targeting
key
players
pathogenesis,
including
amyloid-β
(Aβ),
tau
neuroinflammation
modulators.
We
emphasized
efficacy
lecanemab
donanemab
on
cognition
amyloid
clearance
patients
phase
III
trials
discussed
factors
that
may
contribute
to
side
effects
anti-Aβ
mAbs.
In
addition,
provided
important
information
mAbs
or
inflammatory
regulators
trials,
indicated
against
mid-region
pathogenic
potential
AD.
conclusion,
pathogenesis
offers
a
promising
strategy
effective
treatment.
Signal Transduction and Targeted Therapy,
Journal Year:
2022,
Volume and Issue:
7(1)
Published: Dec. 16, 2022
Aging
is
a
gradual
and
irreversible
pathophysiological
process.
It
presents
with
declines
in
tissue
cell
functions
significant
increases
the
risks
of
various
aging-related
diseases,
including
neurodegenerative
cardiovascular
metabolic
musculoskeletal
immune
system
diseases.
Although
development
modern
medicine
has
promoted
human
health
greatly
extended
life
expectancy,
aging
society,
variety
chronic
diseases
have
gradually
become
most
important
causes
disability
death
elderly
individuals.
Current
research
on
focuses
elucidating
how
endogenous
exogenous
stresses
(such
as
genomic
instability,
telomere
dysfunction,
epigenetic
alterations,
loss
proteostasis,
compromise
autophagy,
mitochondrial
cellular
senescence,
stem
exhaustion,
altered
intercellular
communication,
deregulated
nutrient
sensing)
participate
regulation
aging.
Furthermore,
thorough
pathogenesis
to
identify
interventions
that
promote
longevity
caloric
restriction,
microbiota
transplantation,
nutritional
intervention)
clinical
treatment
methods
for
(depletion
senescent
cells,
therapy,
antioxidative
anti-inflammatory
treatments,
hormone
replacement
therapy)
could
decrease
incidence
turn
healthy
longevity.
Signal Transduction and Targeted Therapy,
Journal Year:
2023,
Volume and Issue:
8(1)
Published: June 30, 2023
Abstract
Amyloid
β
protein
(Aβ)
is
the
main
component
of
neuritic
plaques
in
Alzheimer’s
disease
(AD),
and
its
accumulation
has
been
considered
as
molecular
driver
pathogenesis
progression.
Aβ
prime
target
for
development
AD
therapy.
However,
repeated
failures
Aβ-targeted
clinical
trials
have
cast
considerable
doubt
on
amyloid
cascade
hypothesis
whether
drug
followed
correct
course.
recent
successes
targeted
assuaged
those
doubts.
In
this
review,
we
discussed
evolution
over
last
30
years
summarized
application
diagnosis
modification.
particular,
extensively
pitfalls,
promises
important
unanswered
questions
regarding
current
anti-Aβ
therapy,
well
strategies
further
study
more
feasible
approaches
optimization
prevention
treatment.
General Psychiatry,
Journal Year:
2022,
Volume and Issue:
35(1), P. e100751 - e100751
Published: Feb. 1, 2022
China's
population
has
rapidly
aged
over
the
recent
decades
of
social
and
economic
development
as
neurodegenerative
disorders
have
proliferated,
especially
Alzheimer's
disease
(AD)
related
dementias
(ADRD).
AD's
incidence
rate,
morbidity,
mortality
steadily
increased
to
make
it
presently
fifth
leading
cause
death
among
urban
rural
residents
in
China
magnify
resulting
financial
burdens
on
individuals,
families
society.
The
'Healthy
Action'
plan
2019-2030
promotes
transition
from
treatment
health
maintenance
for
this
expanding
with
ADRD.
This
report
describes
epidemiological
trends,
evaluates
burden
disease,
outlines
current
clinical
diagnosis
status
delineates
existing
available
public
resources.
More
specifically,
examines
impact
ADRD,
including
prevalence,
mortality,
costs,
usage
care,
overall
effect
caregivers
In
addition,
special
presents
technical
guidance
supports
prevention
AD,
provides
expertise
guide
relevant
governmental
healthcare
policy
suggests
an
information
platform
international
exchange
cooperation.
Frontiers in Aging Neuroscience,
Journal Year:
2022,
Volume and Issue:
14
Published: April 12, 2022
Alzheimer's
disease
(AD)
is
the
most
prevalent
form
of
age-related
dementia
in
world,
and
its
main
pathological
features
consist
amyloid-β
(Aβ)
plaque
deposits
neurofibrillary
tangles
formed
by
hyperphosphorylated
tau
protein.
So
far,
only
a
few
AD
treatments
approved
have
been
applied
clinic,
but
effects
these
drugs
are
limited
for
partial
symptomatic
relief
to
patients
with
unable
alter
progression.
Later,
all
efforts
targeting
pathogenic
factors
were
unsuccessful
over
past
decades,
which
suggested
that
pathogenesis
complex.
Recently,
disease-modifying
therapies
(DMTs)
can
change
underlying
pathophysiology
AD,
anti-Aβ
monoclonal
antibodies
(mabs)
(e.g.,
aducanumab,
bapineuzumab,
gantenerumab,
solanezumab,
lecanemab)
developed
successively
conducted
clinical
trials
based
on
theory
systemic
failure
cell-mediated
Aβ
clearance
contributes
occurrence
In
review,
we
summarized
recent
studies
therapeutic
trial
results
mabs
AD.
Specifically,
focused
discussion
impact
aducanumab
lecanemab
pathology
profiles.
The
review
provides
possible
evidence
applying
immunotherapy
analyzes
lessons
learned
from
order
further
study
adverse
Drugs in Context,
Journal Year:
2021,
Volume and Issue:
10, P. 1 - 9
Published: Sept. 30, 2021
Alzheimer's
disease
(AD)
is
the
most
common
cause
for
dementia
worldwide.
Until
recently,
all
approved
treatments
AD
were
symptomatic
and
not
modifying.
On
7
June
2021,
US
FDA
aducanumab,
a
human
IgG1
anti-Aβ
monoclonal
antibody
selective
Aβ
aggregates,
as
first
disease-modifying
treatment
AD.
Aducanumab
in
United
States
of
mild
cognitive
impairment
or
mild-dementia
stage
In
this
Editorial,
we
review
trial
data
aducanumab
controversies
that
its
approval
has
generated.
Clinical Interventions in Aging,
Journal Year:
2022,
Volume and Issue:
Volume 17, P. 797 - 810
Published: May 1, 2022
Abstract:
Aducanumab
is
a
monoclonal
antibody
selective
for
amyloid
β
(Aβ)
aggregates.
In
June
2021,
aducanumab
became
the
first
drug
underlying
pathophysiology
of
Alzheimer's
disease
(AD)
approved
by
US
Food
and
Drug
Administration
(FDA),
under
accelerated
approval
pathway.
The
decision
was
based
on
ability
to
remove
Aβ
plaques,
without
any
evidence
that
clearance
correlated
with
less
cognitive
or
functional
decline.
This
has
generated
considerable
debate
in
scientific
community,
especially
because
results
from
two
Phase
3
trials,
EMERGE
ENGAGE,
were
divergent
and,
even
after
post
hoc
analysis,
data
insufficient
prove
efficacy.
Moreover,
some
researchers
think
this
will
be
an
obstacle
progress
also
demonstrated
concerns
about
cost
its
safety
profile.
European
Medicines
Agency's
rejection
December
2021
just
brought
more
controversy
over
FDA's
decision.
Now,
Biogen
designing
required
confirmatory
study,
named
ENVISION,
which
should
complete
2026.
Despite
controversy,
showed
affect
downstream
tau
pathology,
could
open
doors
combination
therapy
approach
AD
(anti-tau
anti-amyloid
drug).
review
summarizes
clinical
development
until
regulatory
agencies'
decisions,
available
trials
AD.
Keywords:
anti-Aβ
antibody,
ARIA,
Agency,
Administration,
protein
